Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 mai 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
09 mai 2024 16h30 HE
|
Travere Therapeutics, Inc.
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 ...
Travere Therapeutics to Present at Upcoming Investor Conferences
08 mai 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA...
Travere Therapeutics Reports First Quarter 2024 Financial Results
06 mai 2024 16h01 HE
|
Travere Therapeutics, Inc.
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
30 avr. 2024 14h40 HE
|
Spherix Global Insights
EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...
Travere Therapeutics to Report First Quarter 2024 Financial Results
29 avr. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 mars 2024 17h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at Upcoming Investor Conferences
26 févr. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in...
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15 févr. 2024 16h01 HE
|
Travere Therapeutics, Inc.
Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S....
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
08 févr. 2024 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15,...